RxDoctor Payments Data

Rohin Vij, MD

Ophthalmology · Columbus, OHNPI 1912439993

Payments from drug & device makers

$5,558in general payments, 2019–2025

Across 111 payments — averaging $50.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$3K
  • AbbVie$581
  • Alcon$547
  • Tarsus Pharmaceuticals, Inc.$499
  • Oyster Point Pharma, Inc.$349
  • Bausch & Lomb Americas Inc.$287
  • plus $516 from 11 others

What the payments were for

  • Travel & lodging$1,91534%
  • Food & beverage$3,64366%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,558 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$184,999
Medicare patients
471
Services billed
1,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine26$36,240
XiidraLifitegrast27$31,483
LumiganBimatoprost36$21,157
TyrvayaVarenicline Tartrate17$13,533
Prednisolone Acetate222$5,707
MoxifloxacinMoxifloxacin Hcl141$3,993
Travoprost12$3,092
Brimonidine Tartrate39$2,204
Diclofenac Sodium171$1,582
ValacyclovirValacyclovir Hcl12$836
Latanoprost75$503
Ketorolac Tromethamine25$341
Timolol Maleate51$266
Ofloxacin30$222
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha22$178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$581$57,39762 claims
Bausch & Lomb Americas Inc.Xiidra$287$31,48327 claims
Oyster Point Pharma, Inc.Tyrvaya$349$13,53317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →